Antioxidant use in Friedreich ataxia

Lauren Myers, Jennifer M. Farmer, Robert B. Wilson, Lisa Friedman, Amy Tsou, Susan L. Perlman, Sub H. Subramony, Christopher M. Gomez, Tetsuo Ashizawa, George R. Wilmot, Katherine D. Mathews, Laura J. Balcer, David R. Lynch

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.

Original languageEnglish (US)
Pages (from-to)174-176
Number of pages3
JournalJournal of the Neurological Sciences
Issue number1-2
StatePublished - Apr 15 2008


  • Ataxia
  • Cerebellum
  • Clinical trial
  • Idebenone

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Antioxidant use in Friedreich ataxia'. Together they form a unique fingerprint.

Cite this